Adeno-associated virus serotype 9 (AAV9) is highly valued in gene therapy because it can cross the blood-brain barrier. It is primarily used to treat monogenic neurological and neuromuscular disorders, most notably Spinal Muscular Atrophy (SMA). AAV9 vectors deliver functional genetic material to replace or suppress faulty genes. Approved treatments and advanced clinical trials using AAV9 […]
Archive for June, 2026
Adeno-associated virus serotype 9 (AAV9): tool of gene therapy that crosses the BBB
Posted by Michael A. S. Guth on June 4th, 2026
Posted in 
HEOR Survival Statistics and Data Shading
Posted by Michael A. S. Guth on June 4th, 2026
đđĄđđ§ đ đđ«đźđ đŹđĄđšđ°đŹ đ đĄđđłđđ«đ đ«đđđąđš đšđ đ.đđ â đ°đĄđąđđĄ đŹđšđźđ§đđŹ đąđŠđ©đ«đđŹđŹđąđŻđ â đđ§đ đđĄđ đđ«đąđđ„ đŠđđđąđđ§ đŹđźđ«đŻđąđŻđđ„ đ°đđŹ đđ đŠđšđ§đđĄđŹ đąđ§ đđĄđ đđšđ§đđ«đšđ„ đđ«đŠ, đđĄđ đŠđđđĄ đ°đšđ«đ€đŹ đšđźđ đđš đ«đšđźđ đĄđ„đČ đ đđđđąđđąđšđ§đđ„ đŠđšđ§đđĄđŹ đđ đđĄđ đŠđđđąđđ§. đđšđ đČđđđ«đŹ. đđšđ§đđĄđŹ. đđšđŠđđđąđŠđđŹ đ°đđđ€đŹ. The drug costs $28,000/month. If a cancer drug showed “statistically significant survival […]